Across TCGA pan-cancer cohorts, SMC5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMC5 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SMC5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SMC5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, UCEC, and LIHC are the cancer types where SMC5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	II,III,IV	0.514	0.958	<.001	30	view →
UCEC	DFS	Median	II,III,IV	0.896	0.429	.014	20	view →
LIHC	DFS	Median	All	0.162	0.440	.021	3	view →
SKCM	OS	Median	III,IV	0.245	0.721	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SMC5 tumor-vs-normal RNA expression · all SMC5 data types